Dolutegravir / Lamivudine: 8 agencies, 2019–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 5.9 years, from 25 Aug 2019 at NYE METODER (Norway) to 9 Jul 2025 at HAS (France).
No assessment is on file from TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
The file is active: 3 of 10 records date from 2023 or later.
3 distinct indication wordings are recorded for dolutegravir / lamivudine by the agencies that label one in English (AWMSG, PBAC and SMC).
1 of these 10 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
NYE METODER (Norway) was first to assess dolutegravir / lamivudine, on 25 Aug 2019; PHARMAC (New Zealand) did not open a file until 13 Apr 2023 — a wide spread of 3.7 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 4 of 10 dated records fall in 2020 alone.
HAS (France) is the only agency to have returned to dolutegravir / lamivudine, recording 3 separate entries.
8 of the 18 agencies in this archive hold a record for dolutegravir / lamivudine.
The full ledger for dolutegravir / lamivudine reads 8 recommended, 1 not recommended and 1 no benefit.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 9 Jul 2025 | Re-assessment of SMR | SMR substantial · ASMR IV | source |
| PHARMAC (New Zealand) | 13 Apr 2023 | Human Immunodeficiency Virus (HIV-1) infection | PTAC advice: Cost Neutral · decision reached | source |
| PBAC (Australia) | 2020 | Human immunodeficiency virus (HIV) infection | The PBAC recommended amending the listing of dolutegravir with lamivudine (DTG/3TC) to per… | source |
| AWMSG (Wales) | 14 Feb 2020 | Treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weigh… | recommended (limited) | source |
| G-BA (Germany) | 6 Feb 2020 | Dovato — benefit assessment §35a | added benefit: not proven | source |
5 further decisions for dolutegravir / lamivudine, across 4 agencies, are not shown here. They link to 3 further source documents.
Related molecules
- raltegravir — divergent outcome (recommended vs restricted) on a shared indication
- bictegravir / emtricitabine / tenofovir alafenamide — divergent outcome (recommended vs restricted) on a shared indication
- sofosbuvir — same ATC class J05A — Antivirals
- letermovir — same ATC class J05A — Antivirals
- cabotegravir — same ATC class J05A — Antivirals
- tenofovir — same ATC class J05A — Antivirals
Coverage: 10 decisions for dolutegravir / lamivudine from 8 agencies, 2019 to 2025. Data to 7 Sep 2026. ATC class J05A — Antivirals. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.